Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Clinical Study of Entinostat/Placebo in Combination With Exemestane in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer

NCT03538171 is registered in ClinicalTrials.gov with Taizhou EOC Pharma Co., Ltd. as lead sponsor.

NCT NCT03538171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03538171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Clinical Study of Entinostat/Placebo in Combination With Exemestane in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer
Lead sponsor
Taizhou EOC Pharma Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
May 15, 2018
Completion date
March 31, 2023
Enrollment
375 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer